Graft-versus- @entity706 effect of donor lymphocyte infusion in @entity706 relapsed after allogeneic XXXX .

@entity1 @entity8 @entity66 @entity706 @entity1072 @entity2132 @entity1893
Donor lymphocyte infusions (DLI) are used to treat relapsed @entity66 after allogeneic @entity8 ( @entity8 ). We treated seven @entity1 with DLI for indolent @entity1893 relapsed after @entity8 . In available blood and bone marrow samples, @entity706 cells were analysed by real-time quantitative polymerase chain reaction of t(14;18)-positive cells in @entity706 , and by immunophenotyping in small @entity1072 . Before DLI, three @entity1 were treated with chemo- and/or radiotherapy, and one with rituximab. Evaluable responses to pre-DLI therapy were stable disease in one and partial remission (PR) in two @entity1 . Six @entity1 responded to DLI (complete remission (CR) in four and PR in two). After DLI, @entity2132 ( @entity2132 ) occurred in 3/6 @entity1 , classified as grade 2, whereas only limited chronic @entity2132 was seen (n=5). The four continuous CR are lasting for median 65+ (43-89) months. In the remaining @entity1 , not responding to DLI, progressive disease was seen later on; chemotherapy followed by another DLI resulted in CR. In three cases, clinical responses to DLI could be substantiated by molecular or immunophenotypic analysis of @entity706 cells. We conclude that DLI is effective for treatment of @entity706 relapsing after @entity8 .
